Free shippingON ALL ORDERS ABOVE $199 (On Cart Value)
- Additional information
- Product Tag
- Reviews (2)
Daclahep 60 mg (Daclatasvir)
Daclahep (Daclatasvir) is an antiviral medicine that prevents hepatitis C virus (HCV) from multiplying in your body. Daclahep is used to treat genotype 1 and genotype 3 chronic hepatitis C in adults with or without cirrhosis. Daclatasvir is given together with another drug called Sovaldi (sofosbuvir).
Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.
Daclatasvir must be used in combination with other medicines that attack the hepatitis C virus in different ways. If daclatasvir is used on its own there is a high chance that the hepatitis C virus will become resistant to it.
Daclahep (Daclatasvir) is used to treat chronic hepatitis C infections (genotype 1, 3 and 4) in adults with uncomplicated liver disease whose liver is still functioning correctly (compensated liver disease). Daclatasvir may be used in people who have not yet received treatment for their hepatitis C, or for people whose disease has not improved with previous treatment. Daclahep may be used in combination with sofosbuvir (Sovaldi), either with or without ribavirin (Rebetol), or with ribavirin plus peginterferon alfa (ViraferonPeg or Pegasys).
You should not use Daclahep if you are allergic to daclatasvir. If you take daclatasvir with sofosbuvir, there may be other reasons you should not take this combination treatment. Tell your doctor about all your medical conditions.
Some medicines can interact with Daclatasvir and should not be used at the same time. Your doctor may need to change your treatment plan if you use any of the following drugs: rifampin, carbamazepine, phenytoin.
To make sure Daclahep is safe for you, tell your doctor if you have:
- liver problems other than hepatitis C;
- heart disease;
- if you also use amiodarone (a heart rhythm medicine); or
- if you have received a liver transplant.
- It is not known whether Daclahep will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant.
It is not known whether daclatasvir passes into breast milk or if it could harm a nursing baby. Tell your doctor if you are breast-feeding a baby.
Daclatasvir is not approved for use by anyone younger than 18 years old
Daclatasvir is available in 30 and 60mg tablets, and the usual dose is 60mg once daily with or without food. It must be used in combination with other hepatitis C medications and is not effective if taken alone. Treatment should be managed by a doctor who has experience treating hepatitis C. People with HCV genotypes 1 or 4 who are being treated for the first time and do not have liver cirrhosis should take daclatasvir plus sofosbuvir for 12 weeks. Due to limited clinical trial data, there is still uncertainty about the best way to treat people with genotypes 2, 3 or 4.
- What happens if I miss a dose?
Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.
- What happens if I overdose?
Seek emergency medical attention or call to your doctor.
Get emergency medical help if you have signs of an allergic reaction to Daclahep: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Q: What is the Generic Name for the trade name drug “Daklinza” ?
A: Daclatasvir mepesuccinate is Generic Name for the trade name drug Daclahep.
Q: What is the Manufacturer Name of Daclahep ?
A: Daclahep is manufactured by Natco Pharma, India
Q: Is Daclahep approved by FDA?
A: Yes, Daclahep is approved by FDA.
Q: What is the dosage and form of Daclahep is available?
A: Daclahep is available 30 mg & 60 mg film-coated tablets
|Country of Origin|
Chronic hepatitis C virus (HCV) infection
Hetero Drugs Ltd
28 tablets in 1 bottle